NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Quipt Home Medical Corp. (“Quipt” or the “Company”) (NASDAQ: QIPT).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Quipt and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On June 5, ...

The S&P 500 index tracks the stock performance of America's biggest companies, and it has averaged annual gains of roughly 10% over multiple decades. That's pretty darn good performance, enough to more than quintuple an investment over 15 years for those who purchased exchange-traded funds (ETFs) mirroring the index. Some individual stocks, though, have done better than that -- much better. In the table below, you'll see that the S&P 500 has been growing at a much faster rate over the past 15 years compared ...

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Quipt Home Medical Corp and its officers or directors [1] Group 1: Investigation and Claims - Pomerantz LLP is representing investors of Quipt Home Medical Corp in an investigation regarding possible securities fraud [1] - Forager Capital Management, a major shareholder of Quipt, has requested the company to retract a misleading statement related to its acquisition offer [2] Group 2: Stock Performance - Following the news of Forager's request, Quipt's stock price decreased by $0.18, or 8.53%, closing at $1.93 per share on June 5, 2025 [2]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Quipt Home Medical Corp and its officers or directors [1] Group 1: Investigation and Claims - Pomerantz LLP is conducting an investigation on behalf of investors of Quipt Home Medical Corp regarding possible securities fraud [1] - Investors are encouraged to contact Pomerantz LLP for more information about the investigation [1] Group 2: Shareholder Actions - Forager Capital Management, a major shareholder of Quipt, has requested the company to retract a statement made on May 21, 2025, which they claim is false and misleading regarding an acquisition offer [3] - Following the press release from Forager, Quipt's stock price decreased by $0.18, or 8.53%, closing at $1.93 per share on June 5, 2025 [3]

Company Overview - Outset Medical, Inc. is a medical technology company focused on pioneering technology to reduce the cost and complexity of dialysis [3] - The Tablo® Hemodialysis System is FDA cleared for use from the hospital to the home, representing a significant technological advancement in dialysis [3] - Tablo serves as a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere, and by anyone [3] Product Features - The integration of water purification and on-demand dialysate production enables Tablo to function as a "dialysis clinic on wheels" [3] - Tablo features 2-way wireless data transmission and a proprietary data analytics platform, promoting a holistic approach to dialysis care [3] Upcoming Events - Management will present at the Goldman Sachs 46th Annual Healthcare Conference on June 11, 2025, at 11:20 a.m. Eastern time [1] - A live and archived webcast of the presentation will be available on the "Investors" section of the Outset website [2]

Company Overview - GE HealthCare (NASDAQ: GEHC) is a recent spinoff from General Electric, established in 2023, aiming to provide capital appreciation to its shareholders [1] Market Conditions - The company has faced challenges due to recent instability in US tariffs, which may impact its stock performance and overall market strategy [1] Investment Philosophy - The investment approach emphasizes deep research and understanding of business model trends to identify long-term growth opportunities while avoiding risky financial instruments [1]

Core Insights - The article suggests that investors should avoid shares of DENTSPLY SIRONA Inc. (NASDAQ: XRAY) based on a long-term analysis of the company's performance and market sentiment [1] Company Analysis - The author has been tracking DENTSPLY SIRONA Inc. for nearly 7.5 years, indicating a sustained negative outlook on the stock [1] - The author utilizes a software tool that measures market optimism and pessimism, aiming to identify discrepancies between market perceptions and actual outcomes [1] Investment Strategy - The investment approach focuses on companies that are likely to surprise the market positively in the near future, suggesting a strategy that capitalizes on market inefficiencies [1]

Core Viewpoint - Royal Philips announced a share repurchase plan of up to 6 million shares, amounting to approximately EUR 125 million, to fulfill obligations from its long-term incentive plans [1][2]. Group 1: Share Repurchase Details - The share repurchases will occur through one or more forward transactions during the second and third quarters of 2025 [2]. - The execution of the repurchase is in compliance with the Market Abuse Regulation and within the limits authorized by the General Meeting of Shareholders on May 8, 2025 [2]. - Philips anticipates taking delivery of the shares in 2027 [2]. Group 2: Company Overview - Royal Philips is a leading health technology company focused on enhancing health and well-being through innovation [3]. - The company generated sales of EUR 18 billion in 2024 and employs approximately 67,200 people across more than 100 countries [3].

Core Insights - Royal Philips has announced the CE-marking of its SmartCT image reconstruction solution, enhancing decision-making in stroke and neurovascular treatment [1][3] - SmartCT is designed for the Philips Azurion neuro biplane system, providing real-time 3D imaging directly in the Angio suite, which accelerates treatment and improves clarity [2][9] - The technology is already in use at leading stroke centers globally, streamlining workflows and supporting timely interventions, particularly in mechanical thrombectomy procedures [3][4] Product Features - SmartCT 3.0 delivers cone-beam CT imaging in as little as 8 seconds, optimizing image quality for cerebral soft tissue and aiding in the visualization of vessel occlusions [9] - The system includes motion-compensated imaging for restless patients and features like SmartCT Dual Viewer for real-time image fusion and enhanced procedural planning [9] - Philips will showcase SmartCT 3.0 at LINNC Paris 2025, highlighting its capabilities for neuro-endovascular treatments [6] Company Overview - Royal Philips is a leading health technology company focused on improving health and well-being through innovation, with 2024 sales of EUR 18 billion and operations in over 100 countries [10][11] - The company specializes in diagnostic imaging, ultrasound, image-guided therapy, and personal health solutions, employing approximately 67,200 people [11]

LAFAYETTE, La., June 03, 2025 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, today announced it will present at the East Coast IDEAS Investor Conference on Wednesday June 11, 2025 at The Westin Times Square in New York, NY. Viemed’s presentation is scheduled to begin at 11:30am ET. The presentation is webcast and can be accessed through the conference host’s main website: http ...